Pharma BD Deal Intelligence
Servier buys into muscular dystrophy with potentially $2.7B deal. Servier agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to…
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs. StockTitan reported Servier's agreement to acquire Edgewise's muscular dystrophy business…
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal. Edgewise shares jumped 17.9% to an all-time high after announcing the sevasemten…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
On June 1, 2026, Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up to $2.65 billion, comprising a $1.55 billion upfront payment and up to $1.1 billion in regulatory and commercial milestones. The transaction transfers global rights to sevasemten, an orally administered fast skeletal myosin inhibitor in a pivotal Becker muscular dystrophy cohort and a Phase 2 Duchenne muscular dystrophy study, along with related IP, regulatory filings and clinical data. Milestones include up to $200 million tied to Becker labeling, $600 million on Duchenne U.S. approval, and $300 million on annual U.S. net sales exceeding $550 million. The deal is expected to close in Q3 2026 subject to regulatory clearance; Edgewise retains its cardiovascular pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Edgewise Therapeutics, Inc. (this deal) | 2026 | $2.6B | 75 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Symphogen A/S | 2006 | — | 66 |
| Servier / Symphogen A/S | 2020 | — | — |
| Servier / Pieris Pharmaceuticals, Inc. | 2017 | $1.7B | — |
| Servier / IDEAYA Biosciences, Inc. | 2025 | $530M | — |
← Browse all deals · How we score deals
More: 2026 deals · Servier deals · Neurology deals